Filing Flows

Filing Flows › CG Oncology (CGON) › Next earnings date

CG Oncology (CGON) earnings: beat the estimate

CG Oncology (CGON) reported on Nov 6, 2026 and beat the EPS estimate: −$0.64 against −$0.81 (+21.0%). Revenue was $1.6M for Q3 2026, -4% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result+21.0% vs estimate
Beat rate40%

The last report

CG Oncology reported revenue of $1.6M for the third quarter 2026 (-4% Y/Y), net loss $56.9M. How it makes money → · Every quarter →

CG Oncology: EPS against the estimate, last 5 reportsCG Oncology: EPS against the estimate, last 5 reportsEstimateReported−$0.55−$0.57Nov 25−$0.58−$0.51Feb 26−$0.54−$0.71May 26−$0.64−$0.90Aug 26−$0.81−$0.64Nov 26
Latest (Nov 26): Estimate −$0.81, Reported −$0.64.

CG Oncology's latest quarter

CG Oncology, Q3 2026: revenue $1.6M (-4% year over year), net loss $56.9M, operating cash flow −$47.7M. The chart follows the revenue to costs, profit and cash.

Questions

Did CG Oncology beat earnings?

CG Oncology (CGON) reported on Nov 6, 2026 and beat the EPS estimate: −$0.64 against −$0.81 (+21.0%).

When does CGON report earnings?

The next date is not set yet.

Does CG Oncology usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.